Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00343460 | APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer | completed | Phase 3 | 1,428 | Heron TherapeuticsINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04238819 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | completed | Phase 1 / Phase 2 | 47 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 |
| clinicaltrials |
| NCT06612645 | Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors(CMD03) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06715124 | QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | active not recruiting | Phase 1 | 237 | Quanta TherapeuticsINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07269080 | STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study(STM-06) | recruiting | Phase 1 | 28 | University of Illinois at ChicagoOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03833700 | A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) | active not recruiting | Phase 1 | 70 | Eisai Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04294628 | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04469530 | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors(AflacST1903) | recruiting | Phase 2 | 55 | Emory UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04735978 | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | active not recruiting | Phase 1 | 123 | Replimune, Inc.INDUSTRY | 5 | Feb 27, 2026 | clinicaltrials |
| NCT05564468 | Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer | completed | N/A | 100 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05914376 | Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors | active not recruiting | Phase 1 | 24 | Hangzhou Converd Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06410209 | A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | recruiting | Phase 2 | 190 | Children's Oncology GroupNETWORK | 2 | Feb 27, 2026 | clinicaltrials |
| NCT07137195 | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) | active not recruiting | N/A | 47 | Ion Beam ApplicationsINDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07279428 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 33 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07438093 | Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors | not yet recruiting | N/A | 60 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06521554 | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | recruiting | Phase 1 | 200 | Nuvalent Inc.INDUSTRY | 3 | Feb 25, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07434609 | Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 150 | Nanolattix Biotechnology Co., Ltd.INDUSTRY | 0 | Feb 25, 2026 | clinicaltrials |
| NCT04233567 | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | completed | Phase 2 | 17 | Sameek RoychowdhuryOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06409000 | Evaluation of 3D Surface Scanning for Virtual-CT Based Radiation Therapy Treatment Planning | completed | — | 26 | Mayo ClinicOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | terminated | Phase 1 | 17 | Accent TherapeuticsINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06005974 | A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation | terminated | Phase 2 | 18 | Recursion Pharmaceuticals Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07108114 | SLV-324 Treatment of Metastatic Solid Tumors | recruiting | Phase 1 | 70 | Solve TherapeuticsINDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04282018 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | completed | Phase 1 / Phase 2 | 97 | BeiGeneINDUSTRY | 2 | Feb 20, 2026 | clinicaltrials |
| NCT05045963 | Impact of Aminoglycosides in Hypotensive Septic Oncology Patients | completed | — | 232 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05381909 | A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors | terminated | Phase 1 | 157 | BeiGeneINDUSTRY | 5 | Feb 20, 2026 | clinicaltrials |
| NCT07192770 | G-CSF-Induced Bone Pain and Supportive Care Approaches(GCSF-PAIN) | completed | — | 225 | Ankara Etlik City HospitalOTHER_GOV | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07389239 | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. | not yet recruiting | Phase 1 / Phase 2 | 24 | University of ChicagoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | not yet recruiting | Phase 1 | 102 | IntoCell, IncINDUSTRY | 0 | Feb 20, 2026 | clinicaltrials |
| NCT03252938 | Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors(INSIGHT) | active not recruiting | Phase 1 | 83 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT04743466 | Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes | active not recruiting | — | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 21 | PfizerINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT05578092 | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | terminated | Phase 1 | 64 | Mirati Therapeutics Inc.INDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT03445858 | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | completed | Early Phase 1 | 22 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07417501 | Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification | not yet recruiting | Phase 2 | 60 | Tongji HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05100251 | Clinical Trial of WBC100 on Advanced Solid Tumor | terminated | Phase 1 | 68 | Zhejiang UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05638334 | Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours | terminated | Phase 1 | 3 | Institut de Recherches Internationales ServierOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05800964 | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | AmgenINDUSTRY | 9 | Feb 17, 2026 | clinicaltrials |
| NCT07123103 | A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 150 | ExelixisINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07414316 | A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. | recruiting | Early Phase 1 | 10 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03065062 | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | suspended | Phase 1 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04041310 | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 115 | Nouscom SRLINDUSTRY | 6 | Feb 13, 2026 | clinicaltrials |
| NCT05103683 | First in Human Study of TORL-1-23 in Participants With Advanced Cancer | recruiting | Phase 1 | 90 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Feb 13, 2026 | clinicaltrials |
| NCT06358677 | Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors(FACE) | recruiting | Phase 2 | 25 | University of UtahOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06973863 | A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 40 | PharmaEngineINDUSTRY | 2 | Feb 13, 2026 | clinicaltrials |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 59 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407985 | A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors(GK01IIT-TZ03) | active not recruiting | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT02909777 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 2, 2026source: clinicaltrials